Call for EU to ensure maximum benefits are gained from nanomedicine
2 June 2010
European nanomedicine experts have called on the European Parliament to ensure the widespread benefits offered by advances in nanomedicine are used to the best advantage.
Experts from key EU projects gathered in Brussels today at Nanomedicine in Europe to deliver the message.
Hosted by the EU-funded project NanoMed Round Table and the European Parliament Office for Scientific and Technological Option Assessment (STOA), the seminar made recommendations in key areas — applications, health-economic impact, patient needs, regulatory, ethics and communication issues — with a view to enabling EU policy makers to ensure fast translation of R&D results into clinical applications in what has already been identified a major area for strategic investment in the new EU Framework 7 programme for research funding.
The call for action is based on the findings of three European Commission funded projects: NanoMed Round Table, EuroNanoBio, and the Nanomedicine European Technology Platform, which during 2009 gathered information and advice from more than 100 leading experts from academia, industry, regulatory agencies and patient organisations throughout Europe to build the most comprehensive picture to date of the nanomedicine sector.
According to Prof Sir John Beringer, Chair of the Nanomed Round Table, the free exchange and sharing of information and the mutual involvement of the many experts in these and other national and European projects has provided a solid basis for making recommendations for the successful and sustainable competitiveness of nanomedical research and development in Europe and of its healthcare industries.
“Nanomedical applications are not just a theoretical possibility — for example, the Round Table has identified forty-five products that are already on the market. However, the field of nanomedicine is still a relatively new one. This means that Europe is at an ideal moment to consider the impacts and consequences of nanomedicine, as well as action required as a result.
"We believe that action must be taken as soon as possible. By doing too little or too late or nothing, we would significantly risk hindering or even blocking the development of nanomedicine in Europe to the detriment of European research and development, its healthcare industries, and, most importantly, patients — which includes all of us.”
The key recommendations are:
For more information on the NanoMed Round Table project see: www.nanomedroundtable.org/